184
Views
0
CrossRef citations to date
0
Altmetric
Themed Issue: Perspectives from Academic Drug Discovery Conference (Cambridge, UK) – Editorials

The Promise of Open Innovation in Drug Discovery: An Industry Perspective

Pages 1835-1838 | Published online: 30 Sep 2015

References

  • Frye S . US academic drug discovery. Nat. Rev. Drug Disc.10, 409–410 (2011).
  • Austin CP , BradyLS, InselTR, CollinsFS. NIH molecular libraries initiative. Science306, 1138–1139 (2004).
  • Mullarrd A . European Lead Factory opens for business. Nat. Rev. Drug Disc.12, 173–175 (2013).
  • Shanks E , KettelerR, EbnerD. Academic drug discovery within the United Kingdom: a reassessment. Nat. Rev. Drug Disc.14, 510 (2015).
  • Frank R . EU-OPENSCREEN – a european infrastructure of open screening platforms for chemical biology. ACS Chem. Biol.9, 853–854 (2014).
  • Chung TDY . Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford/Burnham: infrastructure, capabilities and operational models. Comb. Chem. High Throughput Scr.17, 272–289 (2014).
  • Hudson J , KhazzraguiHF. Into the valley of death: research to innovation. Drug Disc. Today18, 610–614 (2013).
  • Chesbrough HW . The era of OI. MIT Sloan Management Review44, 35–41 (2003).
  • Schumacher A , GermannPG, GassmannO. Models for OI in the pharmaceutical industry. Drug Disc. Today18, 1133–1137 (2013).
  • Paul SM , MytelkaDS, DunwiddeCTet al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Disc.9, 203–214 (2010).
  • Cook D , BrownD, AlexanderRet al. Lessons learnt from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Disc.13, 419–531 (2014).
  • Simpson PB , ReichmanM. Opening the lead generation toolbox. Nat. Rev. Drug Disc.13, 3–4 (2014).
  • Cumming J , DavisAM, MuresanS, HaeberleinM, ChenH. Chemical predictive modeling to improve compound quality. Nat. Rev. Drug Disc.12, 948–962 (2013).
  • Kojel T , BlombergN, GreasleyPJet al. Big pharma screening collections: more of the same or unique libraries: the AstraZeneca-Baher Pharma AG case. Drug Disc. Today18, 1014–1024 (2012).
  • Gileadi O , KnappS, LeeWHet al. The scientific impact of the Structural Genomic Cnsortium: a protein family and ligand-centred approach to medically-relevant human proteins. J. Struct. Funct. Genomics8, 107–119 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.